Hers vs Willow: Which GLP-1 Provider Is Better?

By Iacob Pastina, Independent Researcher & Publisher

Reviewed & updated August 14, 2026 · Cites primary sources (FDA, NEJM, CMS) · Not medical advice

54 providers verified independently·Independent research·How we rank →

Short answer: Willow scores higher on our rubric, 7.5/10 against 7.3/10. Full reasoning, pricing and the cases where the other one wins are below.

Visit Hers - $188 first month, then $298/mo →or find your match

Willow beats Hers overall, scoring 7.5/10 vs 7.3/10. Published pricing is not a like-for-like monthly comparison: Hers is $188 first month, then $298/mo; Willow is from $299/mo. Choose Hers for women who want a female-focused platform and can budget at least $188 initially and $298/mo ongoing for a $149 medication path. Choose Willow for users who want comprehensive clinical support with flexibility between injectable and oral compounded semaglutide routes.

A side-by-side look at Hers and Willow to help you decide. We compare them on:

•Starting price per month
•Our overall score, out of 10
•Medication type, brand-name or compounded
•Whether they accept insurance
•Who each one is best for

Hers

#30 of 54

7.3/10

The women's health arm of Hims & Hers Health (NYSE: HIMS). Hers lists Wegovy pill, Foundayo, and Ozempic pill medication from $149, a Wegovy pen from $199, Zepbound from $299, and compounded options. A required Weight Loss Membership adds $39 in month one and $149/mo thereafter, so the all-in floor for a $149 medication path is $188 initially and $298/mo ongoing; exact product and dose prices vary.

Visit Hers

Higher Rated

Willow

#20 of 54

7.5/10

Personalized GLP-1 weight loss with ongoing clinical support. Compounded semaglutide and tirzepatide only, Willow explicitly does not prescribe brand-name Wegovy or Zepbound. Added oral compounded semaglutide tablets as a non-injectable option.

Visit Willow

Feature	Hers	Willow
Why each one	A major women-focused telehealth platform with a direct Novo Nordisk partnership (Wegovy pill from $149 and pen from $199 before required membership) and a Lilly partnership (Zepbound medication from $299) alongside compounded options.	One of the few compounded-only platforms offering both injectable and daily oral semaglutide tablets, useful for users who want a non-injectable option without leaving the GLP-1 compounded category.
Our Score	7.3/10	7.5/10
Headline Price	$188 first month, then $298/mo	from $299/mo
Medication Type	Both	Compounded
Insurance Accepted	No	No
Best For	Women who want a female-focused platform and can budget at least $188 initially and $298/mo ongoing for a $149 medication path	Users who want comprehensive clinical support with flexibility between injectable and oral compounded semaglutide routes
Watch out for	Pending federal enforcement action against the parent company. On July 29, 2026 the FTC, joined by Utah and California acting through Los Angeles County Counsel, filed a complaint against Hims & Hers Health, Inc. in the U.S. District Court for the Northern District of California, alleging violations of the FTC Act and the Restore Online Shoppers' Confidence Act over subscription billing, cancellation friction, and sharing consumer health information with advertising platforms. Case status is Pending. These are allegations, not findings.	Compounded-only, no brand-name Wegovy or Zepbound through the platform
Ranking	#30	#20
Get started	Visit Hers	Visit Willow

Pros & Cons Compared

Hers

Pros

+FDA-approved brand paths include Wegovy pill, Foundayo, and Ozempic pill medication from $149 and a Wegovy pen from $199; with the required membership, a $149 medication path totals $188 initially and $298/mo ongoing
+Zepbound access via the Lilly/Hims-Hers partnership announced 2026
+Publicly traded company (NYSE: HIMS) with strong financial backing and regulatory compliance
+Broader women's health platform, integrates weight loss with hormonal, skin, and wellness services

Cons

−Pending federal enforcement action against the parent company. On July 29, 2026 the FTC, joined by Utah and California acting through Los Angeles County Counsel, filed a complaint against Hims & Hers Health, Inc. in the U.S. District Court for the Northern District of California, alleging violations of the FTC Act and the Restore Online Shoppers' Confidence Act over subscription billing, cancellation friction, and sharing consumer health information with advertising platforms. Case status is Pending. These are allegations, not findings.
−Every medication figure excludes the required Weight Loss Membership ($39 first month, then $149/mo); exact product and dose prices can increase the total above the $188/$298 floor
−Support runs at big-platform scale, fine for routine refills, less personal if you want high-touch care
−Compounded pricing starts at $199/mo with stepped pricing at higher doses, budget for the dose you'll end up on, not the entry dose
−Zepbound medication starts at $299 before the required membership; that path totals $338 in month one and at least $448/mo ongoing, with exact dose pricing potentially higher

Willow

Pros

+Includes monthly provider check-ins and dose adjustments at no extra cost
+Offers both injectable AND oral compounded semaglutide, one of few platforms with a daily oral tablet option
+$299/mo all-in for compounded semaglutide with monthly provider support
+90%+ patient retention rate after 3 months per their published outcomes data

Cons

−Compounded-only, no brand-name Wegovy or Zepbound through the platform
−Tirzepatide pricing reaches $499-$524 at higher doses, starting dose is $399/mo
−Cash-pay only, no insurance billing, though they provide superbills for FSA/HSA
−Founded in 2024, less track record than Ro or Hims, though growth has been fast

Our Verdict

Willow edges out Hers with a score of 7.5/10 vs 7.3/10. Published pricing is not a like-for-like monthly comparison: Hers is $188 first month, then $298/mo; Willow is from $299/mo. Hers offers both brand-name and compounded medications, giving you more flexibility.